---
document_datetime: 2026-01-19 11:27:32
document_pages: 22
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/skyrizi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: skyrizi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 13.7015699
conversion_datetime: 2026-01-20 20:16:56.018126
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Skyrizi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0056/G            | This was an application for a group of variations. 1. B.IV.1.c (Type II): To add a presentation of Skyrizi 180 mg solution for injection in a pre-filled syringe for subcutaneous use, which is an integrated part of the primary packaging of the medicinal | 19/06/2025                          |                                             | SmPC, Annex II, Labelling and PL | Product information was updated to reflect the addition of finished product Skyrizi 180 mg solution for injection in prefilled syringe presentations (EU/1/19/1361/008-009); furthermore, product information was updated to add a polysorbate warning statement for parenteral medicinal products for all presentations. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| product (EU/1/19/1361/008); 2. B.II.e.5.a.2 (Type IB): To add a new pack-size of Skyrizi 180 mg solution for injection in a pre-filled syringe for subcutaneous use consisting of 2 pre- filled syringes (EU/1/19/1361/009); 3. C.I.z (Type IB): To add a polysorbate warning statement for parenteral medicinal products for all presentations; 4. B.II.b.2.c.1 (Type IAIN): To add AbbVie Biotechnology GmbH, Knollstrasse, 67061 Ludwigshafen, Germany, as an alternative site responsible for batch release, not including batch control/testing, of the finished product Skyrizi 180 mg solution for injection (EU/1/19/1361/008-009). The requested group of variations proposed amendments to the Summary of Product Characteristics, Annex II, Labelling, Package Leaflet, and Annex A. B.IV.1.c - Change of a measuring or administration device - Addition or replacement of a device which is an integrated part of the primary packaging B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes C.I.z - Changes (Safety/Efficacy) of Human and   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | - Change to importer, batch release and quality control testing of the FP - or addition of a manufacturer for importation and/or batch release - including batch control/testing                                                                                                                                                                                                                                                                                                                                                      |            |     | B.II.b.2.c.1 arrangements Replacement responsible Not   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------|
| II/0054/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch                                  | 22/05/2025 | n/a | control/testing takes                                   |
| II/0052/G | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting | 25/04/2025 | n/a |                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| material/intermediate/reagent approved specifications B.I.d.1.c - Stability of period/storage period to an approved stability B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place A.7 - Administrative change manufacturing sites B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.d.1.e - Change in and/or limits of the finished outside the approved specifications B.II.f.1.e - Stability of stability protocol B.II.b.4.c - Change in size ranges) of the finished requires assessment of biological/immunological bioequivalence study B.I.b.2.a - Change in test starting material/reagent/intermediate   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0053   | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/01/2025   | SmPC and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0050   | Update of sections 4.8 and 5.1 of the SmPC in order to add information based on data of the final study report M15-997 (LIMMITLESS) listed as a category 3 study in the RMP. This is a multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/01/2025   | SmPC          | The following text is updated in SmPC Section 4.8: Immunogenicity • For subjects exposed to long term treatment of risankizumab in the extension study, the immunogenicity profile observed up to 204 weeks of treatment was consistent compared to the first 52 weeks of treatment. The following text is added in SmPC Section 5.1: • Of the patients who received risankizumab in ULTIMMA-1 and ULTIMMA-2, 525 continued to receive risankizumab every 12 weeks in LIMMITLESS. Of these, 376 (71.6%) completed an additional 252 weeks of open- label treatment. Among subjects remaining in the study, improvements achieved with risankizumab in rates of PASI 90 and sPGA of clear or almost clear at week 52 were maintained through week 304. • Of the patients who received ustekinumab in ULTIMMA-1 and ULTIMMA-2, 172 received risankizumab every 12 weeks in LIMMITLESS. Of these, 116 (67.4%) completed the study, including 252 weeks of open-label risankizumab treatment and end of study follow-up. Among subjects remaining in the study, rates of PASI 90 and sPGA response of clear or almost clear increased from week 52 through week 76 and were then maintained through week 304. • Improvements in Dermatology Life Quality Index (DLQI 0 or 1) were maintained in patients receiving continuous risankizumab treatment through wWeek 304 in |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             | For more information, please refer to the Summary of Product Characteristics.                                                              |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10765 /202403 | Periodic Safety Update EU Single assessment - risankizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/11/2024 | 13/01/2025 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10765/202403. |
| IA/0055             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 19/12/2024 | n/a        |             |                                                                                                                                            |
| IA/0051             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 02/10/2024 | n/a        |             |                                                                                                                                            |
| II/0049/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing | 05/09/2024 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  |                                                                                                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------|
| X/0043/G  | This was an application for a group of variations. Extension application to introduce a new strength of 180 mg of risankizumab (solution for injection in cartridge), grouped with a type II variation extension of indication (C.I.6.a) to add a new indication (treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy). As a consequence of the extension of indication, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 5.3, 6.5 and 6.6 of the SmPC are updated. The Annex II, Labelling and Package Leaflets are updated in accordance. In addition, the marketing authorisation holder has taken the opportunity to update the list of local representatives in the PL. The RMP version 5.3 is adopted. Annex I_2.(c) Change or addition of a new strength/potency C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 30/05/2024 | 24/07/2024 | SmPC, Annex II, Labelling and PL | Please refer to the scientific discussion: EMEA/H/C/004759/X/0043/G                                              |
| II/0046/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18/04/2024 | 24/07/2024 | Annex II and                     | Annex II is modified to reflect the inclusion of AbbVie Biotechnology Ltd., Road Number 2, Km 59.2, Barceloneta, |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time   |            |            | Labelling   | Puerto Rico 00617, USA as an alternative site responsible for manufacture of the risankizumab 150 mg/mL active substance. In addition, the MAH took the opportunity to include editorial changes to Annex IIIA (inclusion of information on acceptance of justification regarding Braille).   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0047/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/03/2024 | 24/07/2024 | Annex II    |                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0039              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 09/11/2023 | 05/01/2024 | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Skyrizi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                              |
| X/0033              | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 09/11/2023 | 05/01/2024 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0045             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                              | 30/11/2023 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10765 /202303 | Periodic Safety Update EU Single assessment - risankizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26/10/2023 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0044           | A.z - Administrative change - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 17/10/2023 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0035             | Update of sections 4.8 and 5.1 of the SmPC for 150 mg solution for injection in pre-filled pen and pre- filled syringe and 75 mg solution for injection in pre- filled syringe based on final results from study M15- 997; this is a is a Phase 3, single-arm, multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis. In addition, the MAH took the opportunity to implement editorial changes to the SmPC for all strengths / pharmaceutical forms. | 21/09/2023 | 05/01/2024 | SmPC                             | In study M15-997 (LIMMITLESS), response rates among subjects who completed ULTIMMA-1 and ULTIMMA-2 and continued risankizumab treatment were maintained through week 160, with 88% (460/525) achieving PASI 90 and 88% (462/525) achieving sPGA response of clear or almost clear. For subjects exposed to long term treatment of risankizumab (up to 204 weeks in the extension study), the immunogenicity profile observed was consistent compared to the first 52 weeks of treatment. The safety profile of risankizumab with more than 5 years |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                |            |            |             | of exposure was consistent with the profile observed up to 16 weeks. For more information, please refer to the Summary of Product Characteristics.                                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0042   | B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol                                                                                                                              | 14/09/2023 | 05/01/2024 | SmPC and PL | Section 6.4 of the SmPC is modified to include optional storage out of the refrigerator (up to a maximum of 25°C) for up to 24 hours. Package leaflet has been updated accordingly. |
| IB/0041/G | This was an application for a group of variations. B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.z - Quality change - Finished product - Other                                                                                                   | 25/08/2023 | 05/01/2024 | SmPC and PL |                                                                                                                                                                                     |
| IB/0038/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 06/07/2023 | n/a        |             |                                                                                                                                                                                     |
| IB/0037   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                           | 16/06/2023 | n/a        |             |                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IA/0036   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                       | 16/05/2023   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0034   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                | 04/05/2023   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0031/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                     | 28/03/2023   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0030/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                  | 27/02/2023   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0028   | Update of section 4.8 of the SmPC in order to add rash and urticaria to the list of adverse drug reactions (ADRs) based on a thorough evaluation of all events of rash and urticaria, including clinical trial and post-marketing data from the global safety database; the Package Leaflet is updated accordingly. | 23/02/2023   | 05/01/2024 | SmPC and PL | Based on the cumulative review of cases of rash and urticaria observed in clinical trial data and reported in post- marketing setting, an association between risankizumab and the adverse effects rash and urticaria is considered a possibility. Therefore rash and urticaria are added as new undesirable effects under section 4.8 of the SmPC with a frequency of \"common\" and \"uncommon\" respectively, |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                  |            |            |             | based on pooled clinical trial and post-marketing data. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| IA/0032/G           | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a | 21/02/2023 | n/a        |             |                                                                                                                                         |
| II/0029/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study                                            | 02/02/2023 | n/a        |             |                                                                                                                                         |
| PSUSA/10765 /202203 | Periodic Safety Update EU Single assessment - risankizumab                                                                                                                                                                                                                                                                                                                                                                                                         | 10/11/2022 | 10/01/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for                  |

<div style=\"page-break-after: always\"></div>

|          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        | PSUSA/10765/202203.                                         |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------|
| X/0020/G | Extension application to: - introduce a new pharmaceutical form (concentrate for solution for infusion), a new strength (600 mg) and a new route of administration (intravenous use) - add a new strength of 360 mg for risankizumab solution for injection (in cartridge) for subcutaneous use The above new presentations are indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. The RMP (version 4.5) is updated in accordance. Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(e) Change or addition of a new route of administration Annex I_2.(c) Change or addition of a new strength/potency | 15/09/2022 | 21/11/2022 | SmPC, Labelling and PL | Please refer to Scientific Discussion Skyrizi-H-C-4759-X-20 |
| N/0027   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/08/2022 | 14/10/2022 | PL                     |                                                             |
| IB/0026  | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/08/2022 | n/a        |                        |                                                             |

<div style=\"page-break-after: always\"></div>

|           | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|
| IB/0021   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                             | 13/06/2022 | n/a |                       |
| IB/0023   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                   | 08/06/2022 | n/a |                       |
|           | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                       | 02/06/2022 | n/a | IB/0024/G             |
| II/0019/G | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 03/02/2022 | n/a | batch control/testing |

<div style=\"page-break-after: always\"></div>

| II/0014   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/10/2021   | 15/11/2021   | SmPC, Annex II, Labelling and PL   | Please refer to Scientific Discussion Skyrizi-H-C-4759-II-14   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|----------------------------------------------------------------|
|           | New therapeutic indication for the treatment of active psoriatic arthritis in adults. Consequently sections 4.1, 4.2, 4.8, 5.1 and 5.2 to the SmPC have been updated. The Package leaflet is updated accordingly. Minor update of Annex II is also introduced. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 28/10/2021   | 14/10/2022   |                                    |                                                                |
| II/0017/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - |              |              | Annex II                           |                                                                |

<div style=\"page-break-after: always\"></div>

|                     | the AS -replacement or addition of a site where batch control/testing takes place B.I.c.3.b - Change in test procedure for the immediate packaging of the AS - Other changes to a test procedure (including replacement or addition) B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS   |            |            |             |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10765 /202103 | Periodic Safety Update EU Single assessment - risankizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/10/2021 | n/a        |             | PRAC Recommendation - maintenance |
| II/0018             | B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                | 14/10/2021 | 15/11/2021 | SmPC and PL |                                   |
| II/0015/G           | This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation                                                                                                                                                                                                                                                      | 15/07/2021 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

| X/0012              | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 25/03/2021   | 21/05/2021   | SmPC, Annex II, Labelling and PL   |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------|
| PSUSA/10765 /202009 | Periodic Safety Update EU Single assessment - risankizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 09/04/2021   | n/a          |                                    | PRAC Recommendation - maintenance |
| PSUSA/10765 /202003 | Periodic Safety Update EU Single assessment - risankizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 29/10/2020   | n/a          |                                    | PRAC Recommendation - maintenance |
| II/0010/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 15/10/2020   | 21/05/2021   | Annex II                           |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.k - Change in the starting material/reagent/intermediate storage site of MCB and/or B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.c.1.c - Change in immediate - Liquid ASs (non sterile) B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.3.a - Change in the finished or intermediate   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| PSUSA/10765 /201909   | Periodic Safety Update EU Single assessment - risankizumab                                                        | 17/04/2020   | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------|-------------------------------------------------------------------------------------------------------------------|--------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0008               | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 17/04/2020   | 27/08/2020 | SmPC | This variation is based on data previously submitted during the initial marketing authorisation and regarding the IMMhance study (M15-992): Risankizumab versus placebo in a multicenter randomised double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomised withdrawal and re- treatment. No new clinical data are submitted with this application. The change pertains to the addition of information on retreatment after withdrawal of risankizumab to the summary of the IMMhance clinical study for completeness. The new paragraph introduced is described below: 'Among subjects who achieved a static Physician Global Assessment (sPGA) of clear or almost clear at week 28 and relapsed to sPGA of moderate or severe following withdrawal from risankizumab, 83.7% (128/153) regained sPGA of clear or almost clear after 16 weeks of retreatment. Loss of sPGA of clear or almost clear as early as 12 weeks after withdrawal from risankizumab (one missed dose). Of those subjects who were re-randomised to withdraw from treatment, 80.9% (182/225) relapsed and the median time to relapse was 295 days. No characteristics were identified to predict the time to loss of response or likelihood of regaining response at the individual patient level.\" In addition, a clarification on the duration of the IMMHANCE study after re-randomization is introduced. |
| N/0007                | Minor change in labelling or package leaflet not                                                                  | 29/01/2020   | 27/08/2020 | PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |      |                           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------|
| II/0002/G | This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure addition) | 12/09/2019 | n/a        |      | (including replacement or |
| IA/0006   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 30/08/2019 | 27/08/2020 | SmPC |                           |
| IB/0003/G | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging                                                                                                                                                                                                                                                                                                                                   | 22/08/2019 | n/a        |      |                           |

<div style=\"page-break-after: always\"></div>

|           | (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product   |            |     | components or devices   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------|
| IB/0005/G | application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)          | 19/08/2019 | n/a | This was an             |
| IA/0004   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                  | 04/06/2019 | n/a |                         |
|           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient Change in test procedure for AS or                                | 29/05/2019 | n/a | IA/0001/G B.I.b.2.a -   |

<div style=\"page-break-after: always\"></div>

| starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished   | product procedure   |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------|